A comparative evaluation of the effects of bevacizumab and 5-fluorouracil on wound healing in rat model

Basit Öğe Kaydı
dc.contributor.authorGunay, Ahmet
dc.contributor.authorAtilgan, Serhat
dc.contributor.authorYesilova, Yavuz
dc.contributor.authorYaman, Ferhan
dc.contributor.authorOzgoz, Mehmet
dc.contributor.authorLacin, Nihat
dc.date.accessioned2024-04-24T17:33:10Z
dc.date.available2024-04-24T17:33:10Z
dc.date.issued2012
dc.departmentDicle Üniversitesien_US
dc.description.abstractPurpose: Our aim is to evaluate the use of combined bevacizumab with 5-Fluorouracil (5-FU) on post-operative scarring survival following experimental skin incision surgery in comparison to the agents alone. Material and methods: Skin incision surgery was performed on 28 female Spraque-Dawley rats. The rats were allocated to one of four treatments: 5-FU combined with Bevacizumab, 5FU alone, bevacizumab alone and phosphate buffered saline (PBS). A single subcutaneous injection was administered immediate postoperatively. Histological staining determined the presence of cutaneous fibrosis and mRNA expression of collagen I and fibronectin in the tissue was quantified. Results: Relative quantity of Colla1 mRNA transcript 5 fold increased in Group 1 (PBS) in comparison to control group. However, Colla1 level in Group 2 (5-FU) and 3 (bevacizumab) is decreased. The lowest level of Colla1 was detected in Group 4 (combination of 5-FU and bevacizumab). On the other hand, relative quantity of Fn1 is slightly elevated in Group 1 (PBS) and decreased in Group 2 (5-FU) and group 3 (bevacizumab) in comparison to control group. The lowest level of Fn 1 was detected in Group 4 (combination of 5-FU and bevacizumab). Conclusions: Bevacizumab in combination with 5-FU resulted in a greater anti-fibrotic effect compared to monotherapy with 5FU or bevacizumab alone, as evidenced by the attenuation in fibronectin and mature collagen I expression and deposition. (P<0.05) The results provide compelling evidence that combined bevacizumab and 5-FU offers superior anti-fibrotic effect over monotherapy. A synergistic effect is suggested to be present.en_US
dc.identifier.endpage3945en_US
dc.identifier.issn1840-2291
dc.identifier.issn1986-8103
dc.identifier.issue12en_US
dc.identifier.scopus2-s2.0-84872965339
dc.identifier.scopusqualityN/A
dc.identifier.startpage3937en_US
dc.identifier.urihttps://hdl.handle.net/11468/20492
dc.identifier.volume6en_US
dc.identifier.wosWOS:000314345000007
dc.identifier.wosqualityN/A
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.language.isoenen_US
dc.publisherDrunpp-Sarajevoen_US
dc.relation.ispartofHealthmed
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectBevacizumaben_US
dc.subject5-Fluorouracilen_US
dc.subjectWound Healingen_US
dc.titleA comparative evaluation of the effects of bevacizumab and 5-fluorouracil on wound healing in rat modelen_US
dc.titleA comparative evaluation of the effects of bevacizumab and 5-fluorouracil on wound healing in rat model
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu